UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Predictors of switching antipsychotic medications in the treatment of schizophrenia

BMC psychiatry, 2010-09, Vol.10 (1), p.75-75, Article 75

2010

Volltextzugriff (PDF)

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia

BMC psychiatry, 2009-09, Vol.9 (1), p.54-54, Article 54

2009

Volltextzugriff (PDF)

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia

BMC psychiatry, 2010-01, Vol.10 (1), p.11-11, Article 11

2010

Volltextzugriff (PDF)

Measures of Functioning in Patients With Episodic Migraine: Findings From a Double‐Blind, Randomized, Placebo‐Controlled Phase 2b Trial With Galcanezumab

Headache, 2018-09, Vol.58 (8), p.1225-1235

2018

Volltextzugriff (PDF)

Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs

Journal of managed care & specialty pharmacy, 2019-01, Vol.25 (1), p.46-59

2019

Volltextzugriff (PDF)

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial

BMC medical research methodology, 2012-09, Vol.12 (1), p.142-142, Article 142

2012

Volltextzugriff (PDF)

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia

BMC psychiatry, 2011-09, Vol.11 (1), p.152-152, Article 152

2011

Volltextzugriff (PDF)

Clinical Characteristics and Treatment Patterns Among Patients Diagnosed With Cluster Headache in U.S. Healthcare Claims Data

Headache, 2017-10, Vol.57 (9), p.1359-1374

2017

Volltextzugriff (PDF)

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example

Cost effectiveness and resource allocation, 2009-05, Vol.7 (11), p.11-11

2009

Volltextzugriff (PDF)

Health Care Utilization and Direct Costs Among Patients Diagnosed with Cluster Headache in U.S. Health Care Claims Data

Journal of managed care & specialty pharmacy, 2018-09, Vol.24 (9), p.921-928

2018

Volltextzugriff (PDF)

Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention‐Deficit/Hyperactivity Disorder

CNS neuroscience & therapeutics, 2016-12, Vol.22 (12), p.970-978

2016

Volltextzugriff (PDF)

Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives

Current medical research and opinion, 2010-10, Vol.26 (10), p.2403-2410

2010

Volltextzugriff (PDF)

Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited

Clinical schizophrenia & related psychoses, 2014-07, Vol.8 (2), p.84-90A

2014

Volltextzugriff (PDF)

Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia

Current medical research and opinion, 2008-05, Vol.24 (5), p.1399-1405

2008

Volltextzugriff (PDF)

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians

Patient preference and adherence, 2011-01, Vol.5 (default), p.547-554

2011

Volltextzugriff (PDF)

Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use

Journal of clinical psychopharmacology, 2006-12, Vol.26 (6), p.666-667

2006

Volltextzugriff (PDF)

Clinical Characteristics and Treatment Patterns among Patients with Diagnostic Codes for Cluster Headache in U.S. Healthcare Claims Data (P1.181)

Neurology, 2017-04, Vol.88 (16_supplement)

2017

Volltextzugriff (PDF)

Cost-Effectiveness of Olanzapine as First-Line Treatment for Schizophrenia: Results from a Randomized, Open-Label, 1-Year Trial

Value in health, 2006-03, Vol.9 (2), p.77-89

2006

Volltextzugriff (PDF)

Management of lower pole nephrolithiasis: a critical analysis

The Journal of urology, 1994-03, Vol.151 (3), p.663-667

1994

Volltextzugriff (PDF)

Accuracy of bar codes versus handwriting for recording trauma resuscitation events

Annals of emergency medicine, 1993-10, Vol.22 (10), p.1545-1550

1993

Volltextzugriff (PDF)

Treatment Discontinuation Following Randomization to Open-Label Olanzapine, Risperidone or Typical Antipsychotics During a One-Year Treatment for Schizophrenia

Clinical schizophrenia & related psychoses, 2008-10, Vol.2 (3), p.226-234

2008

Volltextzugriff (PDF)

Alterations in predicted growth rates of pediatric kidneys treated with extracorporeal shockwave lithotripsy

Journal of endourology, 1998-10, Vol.12 (5), p.469-475

1998

Volltextzugriff (PDF)

Cost-Effectiveness of Olanzapine as a First-Line Treatment: A Response to Comment

Value in health, 2006-09, Vol.9 (5), p.358-358

2006

Volltextzugriff (PDF)

Financial analysis of an inner-city helicopter service: Charges versus collections

Annals of emergency medicine, 1989, Vol.18 (1), p.21-25

1989

Volltextzugriff (PDF)

Outcomes of American Lung Association-Indiana Lung Centers asthma program

Disease management, 2005-10, Vol.8 (5), p.311-318

2005

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Aktive Filter

KollektionOxford Journals 2020 Medicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(40)
Berichte
(1)

Sprache

Englisch
(41)

Erscheinungsjahr

n.n

Thema

Humans
(31)
Life Sciences & Biomedicine
(31)
Science & Technology
(31)
Female
(23)
Male
(23)
Adult
(22)
Middle Aged
(16)
Schizophrenia
(12)
Adolescent
(10)
Aged
(10)
Antipsychotic Agents - Therapeutic Use
(9)
Schizophrenia - Drug Therapy
(9)
Biological And Medical Sciences
(8)
Indiana
(8)
Medical Sciences
(8)
Treatment Outcome
(8)
Emergency Medicine
(6)
Health Care Sciences & Services
(6)
Olanzapine
(6)
Antipsychotic
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Predictors of switching antipsychotic medications in the treatment of schizophrenia

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia

Measures of Functioning in Patients With Episodic Migraine: Findings From a Double‐Blind, Randomized, Placebo‐Controlled Phase 2b Trial With Galcanezumab

Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia

Clinical Characteristics and Treatment Patterns Among Patients Diagnosed With Cluster Headache in U.S. Healthcare Claims Data

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example

Health Care Utilization and Direct Costs Among Patients Diagnosed with Cluster Headache in U.S. Health Care Claims Data

Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention‐Deficit/Hyperactivity Disorder

Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives

Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited

Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians

Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use

Clinical Characteristics and Treatment Patterns among Patients with Diagnostic Codes for Cluster Headache in U.S. Healthcare Claims Data (P1.181)

Cost-Effectiveness of Olanzapine as First-Line Treatment for Schizophrenia: Results from a Randomized, Open-Label, 1-Year Trial

Management of lower pole nephrolithiasis: a critical analysis

Accuracy of bar codes versus handwriting for recording trauma resuscitation events

Treatment Discontinuation Following Randomization to Open-Label Olanzapine, Risperidone or Typical Antipsychotics During a One-Year Treatment for Schizophrenia

Alterations in predicted growth rates of pediatric kidneys treated with extracorporeal shockwave lithotripsy

Cost-Effectiveness of Olanzapine as a First-Line Treatment: A Response to Comment

Financial analysis of an inner-city helicopter service: Charges versus collections

Outcomes of American Lung Association-Indiana Lung Centers asthma program

Aktive Filter

Suchergebnisse filtern